Insurers

Five things for pharma marketers to know: Monday, March 20, 2017

Five things for pharma marketers to know: Monday, March 20, 2017

By

Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study

Five things for pharma marketers to know: Friday, March 10, 2017

Five things for pharma marketers to know: Friday, March 10, 2017

By

Novartis' Gleevec shows long-term survival benefit in study; Novo Nordisk CEO considers small acquisitions; Merck KGaA to sell biosimilars unit

Cigna partners with Microsoft HoloLens on biometric game

Cigna partners with Microsoft HoloLens on biometric game

By

The health insurer partnered with Microsoft to use VR and AR technology to gather biometric data.

Five things for pharma marketers to know: Wednesday, February 15, 2017

Five things for pharma marketers to know: Wednesday, February 15, 2017

By

Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto

Infographic: What payers want from pharma

Infographic: What payers want from pharma

One pharmacy director would like to see a lot more comparative data about new therapies.

Five things for pharma marketers to know: Tuesday, January 10, 2017

Five things for pharma marketers to know: Tuesday, January 10, 2017

By

Illumina and IBM enter DNA sequencing partnership; J&J to outline price increases in new report; Egalet's opioid Arymo ER gets FDA approval

Five things for pharma marketers to know: Tuesday, December 13, 2016

Five things for pharma marketers to know: Tuesday, December 13, 2016

By

Lilly to offer discounts for insulin products; Trump reportedly considering Scott Gottlieb to lead FDA; three execs depart Valeant

Five things for pharma marketers to know: Monday, November 7, 2016

Five things for pharma marketers to know: Monday, November 7, 2016

By

Bayer submits Stivarga to FDA for liver-cancer indication; emails show FDA's divisiveness over Duchenne drug approval; insurers want new president to address ACA financial risks

Five things for pharma marketers to know: Wednesday, October 19, 2016

Five things for pharma marketers to know: Wednesday, October 19, 2016

By

Roche gets FDA approval for immunotherapy Tecentriq; insurers are sued for discrimination; the FDA proposes yanking generic ADHD drugs from market

Five things for pharma marketers to know: Friday, September 23, 2016

Five things for pharma marketers to know: Friday, September 23, 2016

By

Anthem and Cigna accuse each other of violating merger terms; Alzheimer's experimental drug fails late-stage study; study calls for new approach to eradicate global epidemics

Five things for pharma marketers to know: Thursday, September 22, 2016

Five things for pharma marketers to know: Thursday, September 22, 2016

By

Mylan CEO comes under fire at House Committee hearing; Abbott OxyContin reps went to great lengths to sell the pain pill; UnitedHealth drops Lantus

Five things for pharma marketers to know: Friday, September 9, 2016

Five things for pharma marketers to know: Friday, September 9, 2016

By

New Cigna campaign features TV doctors; Walgreens to divest 1,000 stores; senators question Aetna's health exchange exit

Five things for pharma marketers to know: Wednesday, August 17, 2016

Five things for pharma marketers to know: Wednesday, August 17, 2016

By

AHIP study says half of orphan-drug usage is for non-orphan indications; Studies of GSK weight-loss pill underestimated side effects; ViiV starts HIV trial

Cigna's first global brand campaign targets expats

Cigna's first global brand campaign targets expats

By

The campaign will run in an integrated digital marketing format using channels such as Facebook, Twitter, and Youtube.

Five things for pharma marketers to know: Tuesday, August 2, 2016

Five things for pharma marketers to know: Tuesday, August 2, 2016

By

IBM develops chip to detect early stages of cancer; Theranos plans to develop a "minilab;" Aetna and Humana to sell $117 million in assets

Five things for pharma marketers to know: Tuesday, July 5, 2016

Five things for pharma marketers to know: Tuesday, July 5, 2016

By

States and insurers are lifting restrictions on HCV drugs; Teva's request to join PhRMA raises eyebrows; Merck partners with GPO

Aetna hires new chief comms officer

Aetna hires new chief comms officer

By

Her hire comes as the insurance giant is merging with Humana in a $37 billion deal.

BodenPR helps UnitedHealthcare educate Hispanic seniors about Medicare

BodenPR helps UnitedHealthcare educate Hispanic seniors about Medicare

By

UnitedHealthcare this month launched a year-long campaign, called Hay Más Adelante.

Five things for pharma marketers to know: Wednesday, May 11, 2016

Five things for pharma marketers to know: Wednesday, May 11, 2016

By

Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies

UnitedHealthcare makes its Oscars debut

UnitedHealthcare makes its Oscars debut

By

The health insurer uses Dirty Dancing, Alien, and Rocky to help consumers navigate the U.S. health system.

New consumer concerns harder for health brands to swallow

New consumer concerns harder for health brands to swallow

By

Finicky formulary committees and rising consumer cost consciousness add up to a new market dynamic for health brands. A new survey helps break it down.

Five things for pharma marketers to know: Friday, July 24

Five things for pharma marketers to know: Friday, July 24

By

UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth

Five things for pharma marketers to know: Tuesday, July 14

Five things for pharma marketers to know: Tuesday, July 14

By

The FDA approves AstraZeneca's Iressa as a first-line lung-cancer therapy; Mylan and Dr. Reddy's launch generic versions of dementia treatment Namenda; health insurer consolidation may lead to pressure on drug prices

Five things for pharma marketers to know: Thursday, July 2

Five things for pharma marketers to know: Thursday, July 2

By

Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs

Inhaled insulin stymied by drive for value

Inhaled insulin stymied by drive for value

By

Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.

Partners+Simons CEO takes helm at parent company Myelin Health

Partners+Simons CEO takes helm at parent company Myelin Health

By

With new leadership in place, the Myelin Health agency network is seeking to acquire other agencies.

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

By

Drugmakers face increasing pressure on pricing from insurers and PBMs.

Better Rx coverage associated with outcomes lift: study

Better Rx coverage associated with outcomes lift: study

By

A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.

MM&M's top reads of 2014

MM&M's top reads of 2014

A look at the content that grabbed most reader interest over the past year.

What payer concerns? Sovaldi ahead of curve

What payer concerns? Sovaldi ahead of curve

By

If the HCV drug's trajectory continues, it could exceed Q1 and 2014 sales forecasts, despite payers' reported unease over price.

OPINION

Gottlieb Likely to Take On Off-Label, Predictability at the FDA

Newsletters